ANPH 101
Latest Information Update: 18 Sep 2006
At a glance
- Originator Ancile Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Sleep disorders
Most Recent Events
- 18 Sep 2006 Discontinued - Phase-III for Sleep disorders in USA (unspecified route)
- 26 Oct 2001 Ancile Pharmaceuticals is seeking a development partner for ANPH 101 (http://www.ancile.com)
- 17 Jul 2001 New profile